Sludge Reports has been in BTX since mid-2013. While suffering some red in the portfolio, shares were added to the position confidently. This long term hold is truly worth holding a long time! There is value to be unlocked for years.
While a Research Report was in the works, yesterday’s Renshaw presentation was truly comprehensive on both the science and investment fronts. BTX is moving from a research phase company into revenue generating phases on some fronts.
Also of note are the insider transactions. Pay particular attention to Neal Bradsher’s (Broadwood) transactions.Neal is a director at Questcor and Biotime (see below). Over the preceding year, Neal moved profits from Questcor into Biotime, adding on some nice dips. Neal is a long term investor in all positions. He isn’t a trader, but rather a long, long term value investor.
BTX is 40% owned by long term investors. Shorts shouldn’t get their hopes up that Neal will sell any shares until we are well into the 2020s.
|Issuer||Filings||Transaction Date||Type of Owner|
|QUESTCOR PHARMACEUTICALS INC||0000891288||2014-08-14||director|
|COMARCO INC||0000022252||2014-08-13||10 percent owner|
|BIOTIME INC||0000876343||2014-07-22||director, 10 percent owner|
|Asterias Biotherapeutics, Inc.||0001572552||2014-06-16||other: See remarks section.|
|STAAR SURGICAL CO||0000718937||2013-12-12||10 percent owner|
|PALOMAR MEDICAL TECHNOLOGIES INC
Current Name:PALOMAR MEDICAL TECHNOLOGIES LLC
|0000881695||2013-06-24||10 percent owner|